Company Overview and News

20
Mesoblast and Tasly Pharmaceutical Group Complete Transaction for Strategic Cardiovascular Partnership in China

2018-10-12 globenewswire - 1
NEW YORK and MELBOURNE, Australia, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced completion of the transaction with Tasly Pharmaceutical Group to establish a strategic partnership in China for Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product candidates MPC-150-IM for heart failure and MPC-25-IC for heart attacks.
MEOBF MSB MESO

19
Trial Results of Mesoblast Cell Therapy in End-Stage Heart Failure Selected as Late-Breaking Presentation at 2018 American Heart Association Scientific Sessions

2018-10-02 globenewswire
NEW YORK and MELBOURNE, Australia, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the 159-patient randomized placebo-controlled Phase 2b trial evaluating its allogeneic mesenchymal precursor cell (MPC) product candidate MPC-150-IM in the treatment of end-stage heart failure patients implanted with a left ventricular assist device (LVAD) has been selected as a late-breaking presentation at the 2018 Scientific Sessions of the American Heart Association being held in Chicago from November 11-13.
MEOBF MSB MESO

19
Mesoblast Heart Failure Cell Therapy for Children Featured at Regenerative Symposium for Congenital Heart Disease

2018-09-25 globenewswire
NEW YORK and MELBOURNE, Australia, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB, Nasdaq:MESO) today announced that Mesoblast's proprietary allogeneic mesenchymal precursor cell (MPC) heart failure product candidate MPC-150-IM for use in children with hypoplastic left heart syndrome (HLHS) was featured at the First Cardiac Regenerative Symposium for Congenital Heart Disease in Baltimore, Maryland on the weekend.
MEOBF MSB MESO

19
Children Treated With Remestemcel-L Continue to Have Strong Survival Outcomes at Six Months in Mesoblast’s Phase 3 Trial for Acute Graft Versus Host Disease

2018-09-20 globenewswire
NEW YORK and MELBOURNE, Australia, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced continued strong survival outcomes through Day 180 in children with steroid refractory acute Graft Versus Host Disease (aGVHD) treated with Mesoblast’s Phase 3 product candidate remestemcel-L, an allogeneic mesenchymal stem cell product candidate.
MEOBF MSB MESO

19
Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction With Mesoblast

2018-09-17 globenewswire
NEW YORK and MELBOURNE, Australia, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that Tasly Pharmaceutical Group has successfully obtained all necessary approvals, including the Safe Administration of Foreign Exchange, required for closing the investment agreement and the development and collaboration agreement with Mesoblast to commercialize cell therapies for cardiovascular diseases in China.
MEOBF MSB MESO

19
Mesoblast Reports Fourth Quarter and Full-Year 2018 Financial Results and Operational Highlights

2018-08-29 globenewswire
MELBOURNE, Australia and NEW YORK, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today reported strong financial results and provided operational highlights for the fourth quarter and full-year ended June 30, 2018 (FY2018).
HTGZ MEOBF MSB HTGC MESO TIG TGXSF HTGX TIG HTGY

19
Mesoblast Provides Update on Transaction With Tasly Pharmaceutical Group

2018-08-29 globenewswire
NEW YORK and MELBOURNE, Australia, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that Tasly Pharmaceutical Group has received People's Republic of China governmental approvals of Overseas Direct Investment from Tianjin Commission of Commerce and Tianjin Development and Reform Commission to enter into an investment agreement as well as a development and collaboration agreement with Mesoblast to commercialize cell therapies for cardiovascular diseases in China.
MEOBF MSB MESO

24
Week In Review: Acletis Raising $457 Million In Hong Kong IPO At $2 Billion Valuation

2018-07-22 seekingalpha - 2
Ascletis BioScience, the Hangzhou biopharma with a novel treatment for hepatitis C, may raise as much as $457 million in its upcoming Hong Kong IPO, a debut offering that values the company at $2 billion. Ascletis will be the first biotech to stage an IPO under Hong Kong's new pre-revenue IPO listing rules. The company plans to offer 224 million shares at between HK$12 and HK$16 each. Further, it was announced that GIC Pte, Singapore's sovereign wealth fund, will buy $75 million of Ascletis' stock as a cornerstone investor.
EOSI MSB MESO ALPN

19
Mesoblast Enters Into Strategic Cardiovascular Alliance for China With Tasly Pharmaceutical Group

2018-07-17 globenewswire
NEW YORK and MELBOURNE, Australia, July 17, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has entered into a strategic alliance with one of China’s largest pharmaceutical companies, Tasly Pharmaceutical Group (SHA: 600535; Tasly), for the development, manufacture and commercialization in China of Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product candidates MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction.
MEOBF MSB MESO

24
Leading Commercial and Transactional Healthcare Executive Shawn Cline Tomasello Joins Mesoblast Board

2018-07-11 globenewswire
NEW YORK and MELBOURNE, Australia, July 11, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that Shawn Cline Tomasello has joined its Board of Directors. With more than 30 years’ experience in the pharmaceutical and biotech industries, Ms Tomasello brings substantial commercial and transactional experience to the Mesoblast board.
MEOBF CELGZ GILD MSB CELG MESO KITE

10
Mesoblast Enters Into US$50M Financing with Novaquest Capital for Commercial Readiness of Remestemcel-l in the Treatment of Acute Graft Versus Host Disease

2018-07-02 globenewswire
NEW YORK and MELBOURNE, Australia, July 02, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced a US$50 million financing from NovaQuest Capital Management, L.L.C. (NovaQuest) for the continued development and commercialization of its allogeneic product candidate remestemcel-L (MSC-100-IV) for children with steroid refractory acute Graft versus Host Disease (aGVHD). NovaQuest was formed in 2000 as a strategic investment unit within Quintiles (now IQVIA), the world’s largest clinical research organization, and became an independent firm in 2010.
HTGZ MEOBF MSB HTGC MESO HTGX HTGY

4
Key Day 100 Survival Outcomes of Phase 3 Trial for Acute Graft Versus Host Disease Presented at 2018 ISSCR Annual Meeting

2018-06-21 globenewswire
NEW YORK and MELBOURNE, Australia, June 21, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced key Day 100 survival outcomes of its Phase 3 trial for remestemcel-L, an allogeneic mesenchymal stem cell product candidate, in children with steroid refractory acute Graft Versus Host Disease (aGVHD). The results are being presented today at the 2018 annual meeting of the International Society for Stem Cell Research (ISSCR), being held in Melbourne from June 20-23.
MEOBF MSB MESO

62
U.S. Healthcare Leader Joseph R. Swedish Joins Mesoblast Board

2018-06-19 globenewswire
NEW YORK and MELBOURNE, Australia, June 19, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that Joseph R. Swedish has joined its Board of Directors. Mr. Swedish has more than two decades of healthcare leadership experience as the CEO for major U.S. healthcare organizations. Most recently, he has served as Executive Chairman, President and CEO of Anthem Inc., a Fortune 33 company and the leading health benefits provider in the U.
ATHTF MEOBF MSB CDW CDWHF MESO ANTM ANTX

11
Financial Results and Operational Highlights for the Third Quarter Ended March 31, 2018

2018-05-30 globenewswire - 1
MELBOURNE, Australia and NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced strong financial results for the nine months ended March 31, 2018 and provided operational highlights for the third quarter ended March 31, 2018.
HTGZ MEOBF MSB HTGC MESO HTGX HTGY

66
Mesoblast Appoints New Chief Financial Officer

2018-05-30 globenewswire
MELBOURNE, Australia and NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced the appointment of Josh Muntner as its new Chief Financial Officer, based in New York.
MEOBF CRFX MSB MESO CFRXW CFRX

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...